CRISPR Therapeutics AG (CRSP) Falls Sharper Than Overall Market: Key Information to Note

CRISPR Therapeutics AG Shares Decline in Recent Trading

During the latest market session, CRISPR Therapeutics AG (CRSP) saw its stock price fall by 5.44% to close at $49.93. This decline was steeper than the S&P 500's modest drop of 0.08%. Meanwhile, the Dow Jones Industrial Average slipped by 0.61%, while the Nasdaq, which is heavily weighted toward technology stocks, edged up by 0.08%.

Recent Performance Overview

Before this session, CRISPR Therapeutics AG's stock had climbed 8.13%, outperforming both the Medical sector, which lost 2.21%, and the S&P 500, which fell by 2.16% over the same period.

Upcoming Earnings and Analyst Expectations

Investors are closely monitoring the company's upcoming earnings announcement. Analysts expect CRISPR Therapeutics AG to post an earnings per share (EPS) of -$1.14, representing a 27.85% improvement compared to the same quarter last year. Current consensus estimates also project revenue to reach $7.32 million, a substantial increase of 741.03% year-over-year.

Annual Forecasts

For the full year, Zacks Consensus Estimates predict a loss of $4.86 per share and revenue of $39.15 million. These figures reflect year-over-year changes of +24.88% in earnings and +1015.33% in revenue, respectively.

Analyst Estimate Revisions

Recent updates to analyst forecasts for CRISPR Therapeutics AG highlight shifting short-term business trends. Upward revisions are often seen as a positive signal for the company's outlook.

Zacks Rank and Stock Movement

Our research indicates that changes in analyst estimates often influence short-term stock performance. The Zacks Rank model incorporates these revisions to provide a practical rating system for investors. The Zacks Rank ranges from #1 (Strong Buy) to #5 (Strong Sell), and has a long-standing record of outperforming the market—stocks rated #1 have delivered an average annual return of 25% since 1988. Over the past month, the consensus EPS estimate for CRISPR Therapeutics AG has dropped by 15.84%. The company currently holds a Zacks Rank of #3 (Hold).

Industry Standing

CRISPR Therapeutics AG operates within the Medical - Biomedical and Genetics industry, which is part of the broader Medical sector. This industry currently holds a Zacks Industry Rank of 144, placing it in the lower 42% among more than 250 industries tracked.

Understanding the Zacks Industry Rank

The Zacks Industry Rank evaluates the strength of various industry groups by averaging the Zacks Ranks of the individual stocks within them. Historically, industries ranked in the top half outperform those in the bottom half by a ratio of 2 to 1.